Get started
REGENERON PHARMACEUTICALSREGENERON PHARMACEUTICALSREGENERON PHARMACEUTICALS

REGENERON PHARMACEUTICALS

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

REGN trade ideas

RectanglePrice is above the .236 of the trend up. Bound in a horizontal trading channel for the time being. Neutral pattern. Some trade inside the rectangle but it will eventually break to one side or the other. No recommendation. EPS (FWD) 42.93 PE (FWD) 17.09 Div Rate (TTM) - Short Interest 1.52% Market Cap $78.35B Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
NASDAQ:REGN
by lauralea
REGN Q3 earnings 11/3 @ 6:30amREGN Q3 September 2022 earnings are on 11/3 at 6:30am. Regeneron Pharmaceuticals (REGN) reported Q2 June 2022 earnings of $9.77 per share on revenue of $2.9 billion. The consensus earnings estimate was $8.53 per share on revenue of $2.8 billion. Revenue fell 44.4% compared to the same quarter a year ago. REGN short entry based on its $754 all time high major resistance level which it didn't even break through during the global covid pandemic in 2020. Plus, the nearest support going into earnings on 11/3 is the SMA50 around $663. Any short term pop up is an opportunity to get a higher strike put with a further dated expiry imo. Q3 September 2022 Consensus: EPS = $8.77 Revenue = $2.82 B SMA50 = 663.67 SMA100 = 634.61 SMA150 = 649.19 SMA200 = 641.40 52week high = 754.67 52week low = 538.01 Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends... *3x lucky 7s of trading* 7pt Trading compass: Price action, entry/exit Volume average/direction Trend, patterns, momentum Newsworthy current events Revenue Earnings Balance sheet 7 Common mistakes: +5% portfolio trades, capital risk management Beware of analyst's motives Emotions & Opinions FOMO : bad timing, the market is ruthless, be shrewd Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation 7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big, organized desk Reading books, playing chess Sorted watch-list Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price pi RSI - trend momentum TTC - trend channel AlertiT - notification tickerTracker - MFI Oscillator www.tradingview.com
NASDAQ:REGNShort
by Options360
REGN shortREGN short trade based only on technical top resistance levels near its all-time high of $754. The trade duration can take several weeks for a significant pullback. REGN earnings are 11/3 pre-market. A short strategy could be to take an otm put position and then roll the strike up or roll the expiry to further dated every few days until the price drop occurs. Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends... *3x lucky 7s of trading* 7pt Trading compass: Price action, entry/exit Volume average/direction Trend, patterns, momentum Newsworthy current events Revenue Earnings Balance sheet 7 Common mistakes: +5% portfolio trades, capital risk management Beware of analyst's motives Emotions & Opinions FOMO : bad timing, the market is ruthless, be shrewd Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation 7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big, organized desk Reading books, playing chess Sorted watch-list Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price pi RSI - trend momentum TTC - trend channel AlertiT - notification tickerTracker - MFI Oscillator www.tradingview.com
NASDAQ:REGNShort
by Options360
Regeneron USA Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series Focus: Worldwide By Sun Storm Investment Research & NexGen Wealth Management Service A Profit & Solutions Strategy & Research Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures | USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision. #debadipb #profitsolutions
NASDAQ:REGN
by Sunstorminvest
Regeneron ShortNASDAQ:REGN Regeneron looks like it may be topping out here. Price is navigating through an ascending wedge over the last two weeks of trading. Both the MACD & RSI are showing bearish divergence building over that same timeframe. In addition, the RSI is falling out of overbought territory while the MACD looks primed to cross under the signal line. Daily candles have begun peeling away from the upper Bollinger Band. Price is just under the median line of the (White) Modified Schiff Pitchfork, which has been a reversal area in the not so distant past. Full view of Pitchfork: Thus far, price has just missed testing the median line. A failure to tap that median line would signal a strong downside is imminent. (Hagopian Law) If that occurs, I suspect a strong price decline to the lower paramedian line of the Modified Schiff Pitchfork. (White) I placed the (Blue) Andrews Pitchfork on the recent pivots points to show the potential path price could take on it's journey to the lower paramedian line. A drop out of the ascending wedge will trigger my short entry. My take profit level would be at the lower paramedian line between $635 - $650 depicted by the green box and red bullseye.
NASDAQ:REGNShort
by Cousin_Fat_Fat
3
REGN: volatility squeeze?The Bollinger Band Squeeze occurs when volatility falls to low levels and the Bollinger Bands narrow. Periods of low volatility are often followed by periods of high volatility. Therefore, a volatility contraction or narrowing of the bands can foreshadow a significant advance or decline. Once the squeeze play is on, a subsequent band break signals the start of a new move. A new advance starts with a squeeze and subsequent break above the upper band. RSI leaves enough room for upside price potential. Above 600 supports a bullish trend direction.
NASDAQ:REGNLong
by Peet_Serfontein
Cup and HandlePrice is not to long entry level yet which would be over the left side, or sell side of the cup. Known to be volatile like biotech tends to be. Negative volume is high showing interest. Short interest is 1.57%. Estimated earnings 2-3-22 BMO. (before market opens) There should be strong support at mid cup which is 5582.82 and at the handle low (HL) The cup depth is 223.64. No recommendation. The alligator is trying to tangle which can suggest consolidation of price.
NASDAQ:REGNLong
by lauralea
2